Viva Biotech Holdings engages in the discovery, development, and manufacturing of clinical drugs. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2019-05-09. The firm has two segments. The Drug Discovery Services segment provides structure-based drug discovery services to biotech and pharmaceutical clients for preclinical innovative drug development. The Contract Design and Manufacturing (CDMO) and Commercialization Services segment is engaged in contract development and manufacturing services for small molecule Active Pharmaceutical Ingredients (APIs) and intermediates, as well as the trading of APIs, intermediates and finished products. The firm conducts business primarily in the United States, China, Europe and other regions.
